- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06518421
Emotion and Memory in Chronic Neuropathic Pain
The Role of Limbic Subcortical Structures and Cognition in Chronic Neuropathic Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chronic pain affects 1 in 4 Canadians leading to severe personal and societal consequences. Over 70% of patients with chronic pain report cognitive deficits including memory difficulties and fear of having unexpected pain. However, the impact of chronic pain on cognition has not been adequately studied. Trigeminal neuralgia (TN), a severe facial pain with clear surgical outcomes, is an ideal model to address this question. Limbic structures, including the hippocampus (HPC) and amygdala (AMG), link emotion-memory and pain. Our prior CIHR-funded research revealed significant HPC volume reduction that normalized with successful treatment and abnormal HPC activity and AMG volume in chronic pain. These findings provide the foundation for a better understanding of the limbic subcortical structures and neuronal mechanisms of chronic pain.
Multimodal neuroimaging techniques have emerged as important tools for studying brain abnormalities in TN - seeking to elucidate the underlying neural mechanisms of HPC and AMG alterations, along with emotion-memory processes. This will be the first comprehensive study of limbic subcortical structural alterations and cognition in chronic pain.
Goal(s)/Research Aims
Our overall goal is to uncover the underlying neural mechanism of HPC and AMG alteration in TN and how these relate to chronic pain pathophysiology and cognition. Our specific aims are:
- To characterize abnormalities in HPC subfields and their associated link with memory-specific performance in TN patients and their potential resolution following surgery.
- To investigate the role of the AMG in pain-related fear in TN patients pre- and post-surgery and their associated link with the treatment outcomes.
- To determine the relationship between the alterations in HPC subfields and the amygdaloid complex, and emotion-memory processes in TN patients pre- and post-surgery.
Methods/Approaches/Expertise The investigators will prospectively analyze brain imaging, clinical, and cognitive data from 340 participants (170 TN and 170 healthy age-/sex-matched controls). Patients will be scanned and assessed pre- and 6 months post-surgical treatment for TN.
In Aim 1, HPC subfield volumes will be extracted to characterize regional abnormalities in TN patients. The investigators will use HPC-sensitive memory tasks, including the mnemonic similarity task and the Rey Auditory Verbal Learning Test , to explore whether the HPC-specific memory processes correlate with structural abnormalities outlined.
In Aim 2, AMG nuclei volumes will be extracted to characterize regional abnormalities in TN patients. Fear of pain questionnaires and the Pain Catastrophizing Scale will be used to explore the link between pain-related fear and chronic pain.
In Aim 3, a validated fMRI task designed for episodic simulation based on novel word-pain associations will be used to examine the relationship between the abnormalities in the HPC subfields and AMG nuclei, and emotion-memory processes in TN patients pre- and post-surgery.
The NPA is a neurosurgeon and scientist with a strong clinical research focus on chronic pain. The team has expertise in chronic pain, brain imaging, cognition, and multivariate statistics.
Expected Outcomes Our innovative proposal interfaces brain imaging with cognition. Knowledge of the relationships between limbic structures, cognition, and pain will revolutionize pain assessment and treatment decisions. Uncovering neural mechanisms of HPC- and AMG-related structures in pain may improve healthcare delivery and patient outcomes by providing objective insights complementing current clinical care.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jacob Kim, BSc
- Phone Number: 2927 4163404907
- Email: jacob.kim@uhn.ca
Study Contact Backup
- Name: Patcharaporn Srisaikaew, PhD
- Phone Number: 2927 4163404907
- Email: patcharaporn.srisaikaew@uhn.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5T2S8
- Recruiting
- Toronto Western Hospital
-
Contact:
- Jacob Kim, BSc
- Phone Number: 2927 4166035800
- Email: jacob.kim@uhn.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
- Healthy control will be recruited from the local community
- Patients with Trigeminal neuralgia will be recruited through our Neurosurgery and Pain Clinic at Toronto Western Hospital, University Health Network
Description
Inclusion Criteria (for HC and TN):
- Age between 35 and 60 years old
- Absence of other active major neurological or psychiatric disorders
- Absence of MRI contraindications
- Able to communicate sufficiently to complete tasks and questionnaires
- Montreal Cognitive Assessment (MoCA) score greater than 23/30 (MoCA ≤23/30 could indicate severe cognitive impairment)
Inclusion Criteria for TN:
- Experiencing TN pain over a period of 6 months
- Stable medication use
- Meet established diagnostic criteria for TN (ICHD-3)
Exclusion Criteria (both HC and TN):
- Presence of other chronic pain/headache conditions
- Untreated hypertension or diabetes mellitus
- History of chronic drug or substance use disorder, chronic use of opioids or steroids, head trauma affecting cognitive performance,
- History/presence of active psychiatric illness and/or current use of psychoactive medication
- History of multiple sclerosis, skull base injury or tumours
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Healthy Controls
Brain imaging, clinical data, and cognitive data will be prospectively collect and analyze in both healthy control and patients with trigeminal neuralgia groups. Prospective data collection for control group includes:
|
Magnetic Resonance Imaging is a noninvasive medical imaging test that produces detailed images of almost every internal structure in the human body, including the organs, bones, muscles and blood vessels.
MRI scanners create images of the body using a large magnet and radio waves.
|
|
Trigeminal Neuralgia
Trigeminal Neuralgia is the most common chronic neuropathic facial pain disorder, characterized by the sudden onset of intermittent, intense, shock-like pain in distributions of the trigeminal nerve branches. TN has several unique features that distinguish it as an ideal model for the study of chronic pain: TN is largely unilateral; is severe in its nature; has stereotypical presentation among patients; and is not associated with other sensory deficits observed in other chronic pain disorders, such as numbness. Brain imaging, clinical data, and cognitive data will be prospectively collect and analyze in both healthy control and patients with trigeminal neuralgia groups. Prospective data collection for TN group includes:
|
Magnetic Resonance Imaging is a noninvasive medical imaging test that produces detailed images of almost every internal structure in the human body, including the organs, bones, muscles and blood vessels.
MRI scanners create images of the body using a large magnet and radio waves.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Beck Depression Inventory
Time Frame: For HC and TN > Neuropsychological assessments at baseline to screen for inclusion/exclusion criteria
|
The Beck Depression Inventory (BDI) will be included in our battery of neuropsychological assessments that will be conducted on both HC and TN groups to screen for study inclusion and exclusion criteria.
The BDI consists of 21 questions on which patients must score themselves on a scale from zero to three.
The BDI is scored out of 63 with a score over 31 representing severe depression.
|
For HC and TN > Neuropsychological assessments at baseline to screen for inclusion/exclusion criteria
|
|
Behavioural Inhibition System
Time Frame: For HC and TN > Neuropsychological assessments at baseline to screen for inclusion/exclusion criteria
|
The Behavioural Inhibition System (BIS) will be included in our battery of neuropsychological assessments that will be conducted on both HC and TN groups to screen for study inclusion and exclusion criteria.
The BIS is a 20 question, self-assessment that measures trait sensitivity levels of the behavioral inhibition and activation systems.
|
For HC and TN > Neuropsychological assessments at baseline to screen for inclusion/exclusion criteria
|
|
Anxiety Sensitivity Index
Time Frame: For HC and TN > Neuropsychological assessments at baseline to screen for inclusion/exclusion criteria
|
The Anxiety Sensitivity Index (ASI) will be included in our battery of neuropsychological assessments that will be conducted on both HC and TN groups to screen for study inclusion and exclusion criteria.
The ASI is a six item scale that can outline different concerns someone could have regarding their anxiety.
|
For HC and TN > Neuropsychological assessments at baseline to screen for inclusion/exclusion criteria
|
|
Beck's Hopelessness Scale
Time Frame: For HC and TN > Neuropsychological assessments at baseline to screen for inclusion/exclusion criteria
|
The Beck Hopelessness Scale (BHS) will be included in our battery of neuropsychological assessments that will be conducted on both HC and TN groups to screen for study inclusion and exclusion criteria.
|
For HC and TN > Neuropsychological assessments at baseline to screen for inclusion/exclusion criteria
|
|
Marlowe Crowne Scale
Time Frame: For HC and TN > Neuropsychological assessments at baseline to screen for inclusion/exclusion criteria
|
The Marlowe Crowne Scale (MCS) will be included in our battery of neuropsychological assessments that will be conducted on both HC and TN groups to screen for study inclusion and exclusion criteria.
|
For HC and TN > Neuropsychological assessments at baseline to screen for inclusion/exclusion criteria
|
|
Childhood Trauma Questionnaire
Time Frame: For HC and TN > Neuropsychological assessments at baseline to screen for inclusion/exclusion criteria
|
The Childhood Trauma Questionnaire (CTQ) will be included in our battery of neuropsychological assessments that will be conducted on both HC and TN groups to screen for study inclusion and exclusion criteria.
|
For HC and TN > Neuropsychological assessments at baseline to screen for inclusion/exclusion criteria
|
|
Structural magnetic resonance imaging (MRI)
Time Frame: For HC > MRI at baseline. For TN > MRI at baseline (pre-surgery) and at 6-month post-surgical)
|
The investigators will acquire prospective longitudinal structural imaging data in 170 Trigeminal Neuralgia (TN) (pre-/6-months post-surgery) and 170 healthy controls (HC) and obtain topologies and volumes of the hippocampus (HPC) subfields using the brain imaging analysis software including HippUnfold and FreeSurfer.
The investigators will also analyze amygdala (AMG) nuclei volumes using FreeSurfer.
The group comparisons of the HPC and AMG will be done in both inter-group (TN vs. HC) and intra-group (pre- vs. post-surgery).
|
For HC > MRI at baseline. For TN > MRI at baseline (pre-surgery) and at 6-month post-surgical)
|
|
Mnemonic Similarity Test
Time Frame: For HC > MRI at baseline. For TN > MRI at baseline (pre-surgery) and at 6-month post-surgical)
|
The Mnemonic Similarity Test will be used to compare HPC-dependent memory performance between TN and HC and examine the effect of surgery (pre- and post-) on performance.
The investigators will assess whether HPC-dependent memory and HPC volumes/topologies normalize following surgical TN pain relief.
|
For HC > MRI at baseline. For TN > MRI at baseline (pre-surgery) and at 6-month post-surgical)
|
|
Fear of Pain Questionnaire III
Time Frame: For HC > pain-related fear and anxiety assessments at baseline. For TN >> pain-related fear and anxiety assessments at baseline (pre-surgery) and at 6-month post-surgical
|
The Fear of Pain Questionnaire III (FPQ-III) will be used as one of the pain-related fear and anxiety assessments to assess pain-related fear and anxiety in TN and HC groups.
The investigators will assess whether the abnormalities of the AMG nuclei volume will be normalized after surgery and will correlate these findings with validated pain-related fear and anxiety assessments.
The FPQ-III is a 30 item assessment on which individuals rate how fearful they are of certain pain experiences on a scale from one to five.
|
For HC > pain-related fear and anxiety assessments at baseline. For TN >> pain-related fear and anxiety assessments at baseline (pre-surgery) and at 6-month post-surgical
|
|
Pain Catastrophizing Scale
Time Frame: For HC > pain-related fear and anxiety assessments at baseline. For TN >> pain-related fear and anxiety assessments at baseline (pre-surgery) and at 6-month post-surgical
|
The Pain Catastrophizing Scale (PCS) will be used as one of the pain-related fear and anxiety assessments to assess pain-related fear and anxiety in TN and HC groups.
The investigators will assess whether the abnormalities of the AMG nuclei volume will be normalized after surgery and will correlate these findings with validated pain-related fear and anxiety assessments.
The PCS will help investigators quantify an individual's pain - how they feel and what they think about when experiencing something painful.
|
For HC > pain-related fear and anxiety assessments at baseline. For TN >> pain-related fear and anxiety assessments at baseline (pre-surgery) and at 6-month post-surgical
|
|
State-Trait Anxiety Inventory
Time Frame: For HC > pain-related fear and anxiety assessments at baseline. For TN >> pain-related fear and anxiety assessments at baseline (pre-surgery) and at 6-month post-surgical
|
The State-Trait Anxiety Inventory (STAI) will be used as one of the pain-related fear and anxiety assessments to assess pain-related fear and anxiety in TN and HC groups.
The investigators will assess whether the abnormalities of the AMG nuclei volume will be normalized after surgery and will correlate these findings with validated pain-related fear and anxiety assessments.
The STAI is commonly used to measure trait and state anxiety.
This assessment consists of 20 items for assessing trait anxiety and 20 for state anxiety, each of which are rated on a 4-point scale.
|
For HC > pain-related fear and anxiety assessments at baseline. For TN >> pain-related fear and anxiety assessments at baseline (pre-surgery) and at 6-month post-surgical
|
|
Pain Anxiety Symptoms Scale
Time Frame: For HC > pain-related fear and anxiety assessments at baseline. For TN >> pain-related fear and anxiety assessments at baseline (pre-surgery) and at 6-month post-surgical
|
The Pain Anxiety Symptoms Scale (PASS-20) will be used as one of the pain-related fear and anxiety assessments to assess pain-related fear and anxiety in TN and HC groups.
The investigators will assess whether the abnormalities of the AMG nuclei volume will be normalized after surgery and will correlate these findings with validated pain-related fear and anxiety assessments.
The Pass-20 is a 20 item assessment that measures 4 distinct components of pain-related anxiety.
|
For HC > pain-related fear and anxiety assessments at baseline. For TN >> pain-related fear and anxiety assessments at baseline (pre-surgery) and at 6-month post-surgical
|
|
Functional Magnetic Resonance Imaging (fMRI)
Time Frame: For HC >ES task-fMRI at baseline. For TN >> ES task-based fMRI at baseline (pre-surgery) and 6-months post-surgery
|
The experimental functional magnetic resonance imaging (fMRI) task that is specifically designed to measure episodic simulation (ES) using both neutral and pain-related cues will be conducted.
ES measures the capacity to imagine specific future personal events and is heavily dependent on limbic integrity.
This, along with the recalled pain memory interview will allow the investigators to correlate task-based fMRI findings with pain-recall discrepancies (discrepancies between recalled and initial pain ratings) and surgical response.
|
For HC >ES task-fMRI at baseline. For TN >> ES task-based fMRI at baseline (pre-surgery) and 6-months post-surgery
|
|
Recalled pain memory interview
Time Frame: For HC > recalled pain at baselines. For TN >> recalled pain at baseline (pre-surgery) and at 2 weeks and 6-month post-surgery
|
The recalled pain interview, focused on the recall of pain events, will be conducted and analyzed with a specific focus on the discrepancies in pain recall (referred to as autobiographical memory, AM).
Recalled Pain questionnaires will take place at baseline (~1 week prior to surgery, for the recall of pain onset and experience), acute recovery (2 weeks post-surgery) and 6 months post-surgery for recalled pain.
These interview questionnaires will assess pain frequency, duration, intensity, fear, anxiety, unpleasantness, and interference.
|
For HC > recalled pain at baselines. For TN >> recalled pain at baseline (pre-surgery) and at 2 weeks and 6-month post-surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Structural Magnetic Resonance Imaging Cont.
Time Frame: For HC > MRI at baseline. For TN > MRI at baseline (pre-surgery) and at 6-month post-surgical)
|
Group correlation between other AMG nuclei volumes and pain-related fear and anxiety questionnaires will be performed.
The investigators will assess whether the abnormalities of other AMG nuclei volumes will be normalized after surgery and/or correlated with the validated pain-related fear and anxiety assessments.
|
For HC > MRI at baseline. For TN > MRI at baseline (pre-surgery) and at 6-month post-surgical)
|
|
The Rey Auditory Verbal Learning Test (RAVLT)
Time Frame: For HC > RAVLT at baseline. For TN > RAVLT at baseline (pre-surgery) and at 6-month post-surgical)
|
Group correlation between other HPC subfield volumes and a second HPC-specific memory task using the Rey Auditory Verbal Learning Test (RAVLT) will be performed to evaluate multiple episodic memory functions in both inter-group (TN vs. HC) and intra-group (pre- vs. post-surgery).
|
For HC > RAVLT at baseline. For TN > RAVLT at baseline (pre-surgery) and at 6-month post-surgical)
|
|
Whole brain cortical-based analysis
Time Frame: For HC > MRI at baseline. For TN > MRI at baseline (pre-surgery) and at 6-month post-surgical)
|
Group comparisons of other limbic structures will be performed, using the whole brain cortical-based analysis with a focus on the thickness of the anterior cingulate (ACC), insular, and medial prefrontal cortex (mPFC) cortices.
The investigator will be focused on the dynamic changes of the cortical thickness in TN between i) TN vs. HC, and ii) pre- vs. post-surgical time points.
|
For HC > MRI at baseline. For TN > MRI at baseline (pre-surgery) and at 6-month post-surgical)
|
|
Impact of COVID-19 on pain population
Time Frame: For HC > COVID-19 related data at baseline. For TN > COVID-19 related data at baseline (pre-surgery) and at 6-month post-surgical)
|
Medical and medication history including COVID-19-related experiences will be collected.
The investigator will also address the biopsychological impacts of COVID-19 in our study cohort.
|
For HC > COVID-19 related data at baseline. For TN > COVID-19 related data at baseline (pre-surgery) and at 6-month post-surgical)
|
|
Sex- and gender-based analysis (SGBA)
Time Frame: For HC ad TN > SGBA at baseline as a part of the demographic data
|
The investigator will target enrollment of a 50% male-to-female ratio.
The investigator will also collect the gender identity data.
SGBA will be conducted in all Aims and the distribution of gender data will determine whether we have sufficient power for detailed analyses.
|
For HC ad TN > SGBA at baseline as a part of the demographic data
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mojgan Hodaie, MD, MSc, Department of Neurosurgery, Toronto Western Hospital, University Health Network
Publications and helpful links
General Publications
- Noorani A, Hung PS, Zhang JY, Sohng K, Laperriere N, Moayedi M, Hodaie M. Pain Relief Reverses Hippocampal Abnormalities in Trigeminal Neuralgia. J Pain. 2022 Jan;23(1):141-155. doi: 10.1016/j.jpain.2021.07.004. Epub 2021 Aug 8.
- Hung PS, Noorani A, Zhang JY, Tohyama S, Laperriere N, Davis KD, Mikulis DJ, Rudzicz F, Hodaie M. Regional brain morphology predicts pain relief in trigeminal neuralgia. Neuroimage Clin. 2021;31:102706. doi: 10.1016/j.nicl.2021.102706. Epub 2021 May 25.
- Vaculik MF, Noorani A, Hung PS, Hodaie M. Selective hippocampal subfield volume reductions in classic trigeminal neuralgia. Neuroimage Clin. 2019;23:101911. doi: 10.1016/j.nicl.2019.101911. Epub 2019 Jun 26.
- Audrain S, McAndrews MP. Schemas provide a scaffold for neocortical integration of new memories over time. Nat Commun. 2022 Oct 2;13(1):5795. doi: 10.1038/s41467-022-33517-0.
- Waisman A, Pavlova M, Noel M, Katz J. Painful reminders: Involvement of the autobiographical memory system in pediatric postsurgical pain and the transition to chronicity. Can J Pain. 2022 Jun 3;6(2):121-141. doi: 10.1080/24740527.2022.2058474. eCollection 2022.
- Noel M, Rosenbloom B, Pavlova M, Campbell F, Isaac L, Page MG, Stinson J, Katz J. Remembering the pain of surgery 1 year later: a longitudinal examination of anxiety in children's pain memory development. Pain. 2019 Aug;160(8):1729-1739. doi: 10.1097/j.pain.0000000000001582.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-7350
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.